Impax Laboratories Inc. (IPXL)

17.90
0.22 1.24
NYSE : Health Technology
Prev Close 17.68
Open 17.72
Day Low/High 17.50 / 18.29
52 Wk Low/High 13.47 / 18.29
Volume 839.29K
Avg Volume 916.90K
Exchange NYSE
Shares Outstanding 73.87M
Market Cap 1.35B
EPS -6.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan

Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan

Impax Laboratories, Clearside Biomedical and Mylan were among the biotech stock movers in premarket trading Wednesday.

CVS Remains Unsure About the Future of Obamacare, CEO Says

CVS Remains Unsure About the Future of Obamacare, CEO Says

The company had a mixed fourth quarter.

Mylan's Shares Rise Despite FTC Investigation

Mylan's Shares Rise Despite FTC Investigation

The drug company saw its stock climb 3% Tuesday on news that it can move ahead with generic Copaxone.

First Week of IPXL September 15th Options Trading

First Week of IPXL September 15th Options Trading

Investors in Impax Laboratories Inc saw new options become available this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.

EpiPen Competitor Auvi-Q Will Return in February, but It'll Cost Insurance Companies Big Bucks

EpiPen Competitor Auvi-Q Will Return in February, but It'll Cost Insurance Companies Big Bucks

The autoinjector will be free for insured patients and those whose annual income is less than $100,000.

Biotech Premarket Movers: SGMO, IPXL, PTLA

Biotech Premarket Movers: SGMO, IPXL, PTLA

Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.

Mylan Crushed by Trump, Cigna and CVS -- All In Two Days

Mylan Crushed by Trump, Cigna and CVS -- All In Two Days

The drug maker's shares have fallen 6.2% since Wednesday's market open.

CVS Is the Latest to Rock Mylan's EpiPen Empire

CVS Is the Latest to Rock Mylan's EpiPen Empire

The price of EpiPens has surged about 25% annually since 2007.

Cigna Will No Longer Cover Mylan's EpiPen

Cigna Will No Longer Cover Mylan's EpiPen

Health insurance giant Cigna said it will no longer cover Mylan's EpiPen.

Cigna Defends Abandoning EpiPen Coverage

Cigna Defends Abandoning EpiPen Coverage

Cigna will now encourage patients to use either Impax's or Mylan's generic autoinjector. Impax offers cheaper prices, but can its manufacturing keep up?

Biotech Premarket Movers: IPXL, SGMO, ARLZ

Biotech Premarket Movers: IPXL, SGMO, ARLZ

Impax Laboratories, Sangamo Therapeutics and Aralez Pharmaceuticals are among the premarket movers in biotech.

GPM Reminds Investors Of The January 9 Deadline In The Class Action Lawsuit Against Impax Laboratories, Inc.

GPM Reminds Investors Of The January 9 Deadline In The Class Action Lawsuit Against Impax Laboratories, Inc.

Glancy Prongay & Murray LLP ("GPM") reminds investors of the January 9, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class") of investors who purchased Impax...

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Impax Laboratories, Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Impax Laboratories, Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Impax Laboratories, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Impax Laboratories, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 9, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Impax Laboratories, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 9, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Impax Laboratories, Inc.

IPXL INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Impax Laboratories, Inc. And A Lead Plaintiff Deadline Of January 9, 2017

IPXL INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Impax Laboratories, Inc. And A Lead Plaintiff Deadline Of January 9, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Impax Laboratories, Inc.

Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against Impax Laboratories, Inc.

Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against Impax Laboratories, Inc.

On November 10, 2016, a class action lawsuit was filed in the United States District Court for the District of New Jersey against Impax Laboratories, Inc.

Impax Searches for a New CEO

Impax Searches for a New CEO

Impax Laboratories CEO G. Frederick Wilkinson steps down amid a Department of Justice generic price-fixing investigation. J. Kevin Buchi, who joined the board last month, was tapped as interim CEO.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Impax Laboratories, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 9, 2017

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Impax Laboratories, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 9, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Impax Laboratories, Inc.

DOJ Files Charges in Generic Drug Price-Fixing Investigation

DOJ Files Charges in Generic Drug Price-Fixing Investigation

Shares of leading generics fall as more charges are expected.

IPXL SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Impax Laboratories, Inc. And A Lead Plaintiff Deadline Of January 9, 2017

IPXL SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Impax Laboratories, Inc. And A Lead Plaintiff Deadline Of January 9, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Impax Laboratories, Inc.

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Impax Laboratories, Inc.

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Impax Laboratories, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Impax Laboratories, Inc.

Impax Laboratories Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Impax Laboratories Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXE, CECE, EMN, FC, NNI, PDCO, SAH, SAMG, WERN Downgrades: ATW, CERN, IPXL, NVO, OMCL, PHII, PHIIK, PLKI, SVT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Impax Laboratories Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Impax Laboratories Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces a class action lawsuit against Impax Laboratories Inc.

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Impax Laboratories Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Impax Laboratories Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces a class action lawsuit against Impax Laboratories Inc.

Rosen Law Firm Files Securities Class Action Lawsuit Against Impax Laboratories, Inc. - IPXL

Rosen Law Firm Files Securities Class Action Lawsuit Against Impax Laboratories, Inc. - IPXL

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of Impax Laboratories, Inc.